BioNTech And Duality Biologics Announced FDA Granted Fast Track Designation For BNT324/DB-1311 For Advanced/Unresectable, Or Metastatic Castration-resistant Prostate Cancer Patients Who Have Progressed On Or After Standard Systemic Regimens
BioNTech And Duality Biologics Announced FDA Granted Fast Track Designation For BNT324/DB-1311 For Advanced/Unresectable, Or Metastatic Castration-resistant Prostate Cancer Patients Who Have Progressed On Or After Standard Systemic Regimens
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.